reztripeptid.hu / Articles / Analysis

'Removed From the List' Is Not 'Approved': Reading Peptide News

Procedural withdrawals do not equal safety clearance; understanding the distinction between enforcement discretion and FDA approval is critical for accurate risk assessment.

By Zoltán Varga2026-11-054 min read

The Procedural Shift in April 2026

In early 2026, the US regulatory environment for peptides underwent a significant procedural shift. On April 15, the Food and Drug Administration announced that twelve specific peptides would be removed from Category 2 of the bulk drug substances list. This category had previously identified substances posing significant safety risks for compounding. The removal took effect on April 22, 2026. The official rationale stated that the parties who originally nominated these substances for restriction had withdrawn their nominations. The agency did not conduct new safety studies to justify this change. The substances included BPC-157, TB-500, injectable GHK-Cu, KPV, MOTS-c, Semax, Epitalon, DSIP, LL-37, Dihexa, PEG-MGF, and Melanotan II. None of these substances were automatically moved to Category 1, which would imply a lower risk profile suitable for broader compounding.

Withdrawal of Nominations Versus Safety Findings

A common misconception equates the withdrawal of a nomination with a positive safety finding. The April 2026 update clarified that the removal was purely administrative. The FDA explicitly noted that no new safety data was generated to support the decision. The original nominations often came from industry groups or third parties concerned about specific risks. When these groups withdrew their complaints, the regulatory basis for keeping the substances on the restricted list evaporated. This process does not validate the safety or efficacy of the compounds. It simply removes the specific administrative barrier created by those nominations. The substances remain unapproved new drugs under federal law. Their chemical structure and biological activity have not changed. The absence of a restriction on a specific list does not grant a license to manufacture or sell.

• The removal was triggered by the withdrawal of nominations, not by new clinical data.
• No safety evaluation was performed by the FDA prior to the April 2026 update.
• Substances removed from Category 2 are not automatically placed in Category 1.

How Headlines Reframed Administrative Changes

Media coverage of the April 2026 event frequently obscured the procedural nature of the change. Headlines often suggested that the FDA had 'legalized' or 'approved' these peptides. This framing ignored the distinction between administrative list management and drug approval. Some reports focused on statements made by HHS leadership during public appearances, interpreting political announcements as regulatory finality. The narrative shifted from 'withdrawal of nominations' to 'safety clearance.' This misrepresentation created confusion among consumers and practitioners. The reality is that the substances remain outside the standard approval pathway. The regulatory status is complex and subject to further review. The temporary nature of the policy changes was often omitted from initial reports. The distinction between a procedural update and a scientific endorsement is critical for accurate interpretation.

Advisory Votes and Final Rules

Following the administrative removal, the Pharmacy Compounding Advisory Committee held a meeting in July 2026. The committee reviewed seven of the previously listed peptides. The FDA's scientific staff voted unanimously against adding any of these substances to the list of allowable bulk drugs for compounding. Despite this scientific recommendation, the committee voted to recommend six of the seven substances for inclusion. The votes were narrow, with some decisions split 8-6-1. The committee recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. DSIP was rejected. These recommendations are advisory and do not constitute final rules. The FDA has not yet issued a final regulation based on these votes. The committee's composition faced criticism regarding potential conflicts of interest. The divergence between the scientific staff and the committee highlights the complexity of the decision-making process. The final rulemaking remains pending.

• FDA scientific staff unanimously opposed the addition of the peptides.
• The advisory committee recommended six substances despite staff opposition.
• No final rule has been issued by the FDA as of late 2026.

Enforcement Discretion and Current Status

In October 2026, the Department of Health and Human Services announced a draft policy of interim enforcement discretion. This policy applies to the six peptides recommended by the advisory committee. Under this draft, the agency will not take action against licensed compounding pharmacies that prepare these substances under strict conditions. The conditions include single-active ingredient products, specific routes of administration, and requirements for quality testing and adverse event reporting. This policy is temporary and remains in effect only until a final rule is issued. It does not apply to the 'research use only' market. Selling these substances for human consumption without a prescription remains illegal. The policy does not change the fact that these are unapproved drugs. The gray market continues to face enforcement actions, including warning letters and criminal prosecutions. The distinction between compounding under discretion and commercial sale is absolute.

• Enforcement discretion is a temporary policy, not a permanent rule.
• Strict conditions apply to compounding under the interim policy.
• The 'research use only' market remains subject to enforcement.

A Reading Rule for Regulatory Headlines

Consumers and researchers must apply a strict reading rule when encountering regulatory news. Any headline claiming 'approval' or 'legalization' based on a list removal requires verification of the underlying mechanism. Check whether the change resulted from a safety study or an administrative withdrawal. Look for the specific date of the Federal Register notice. Verify if the substance appears on the final bulk drug substances list or if it is merely under enforcement discretion. Be wary of sources that conflate advisory votes with final regulations. Understand that 'removed from a restricted list' is not synonymous with 'safe for use.' The regulatory landscape is dynamic, with ongoing litigation and policy reviews. Reliance on secondary summaries without checking primary sources leads to misinformation. The burden of verification lies with the reader.

• Verify if the change was administrative or based on safety data.
• Check the Federal Register for the specific regulatory language.
• Distinguish between advisory recommendations and final rules.

AI-assisted: drafted with a language model from the author's research notes, then edited and checked before publication. Author: Zoltán Varga, AI visibility researcher and AI ecosystem architect, Budapest.